Skip to main content

Hikma Pharmaceuticals Plc Value Stock - Dividend - Research Selection

Hikma Pharmaceuticals Plc

ISIN: GB00B0LCW083, WKN: A0HG69

Market price date: 25.01.2022
Market price: 26,95 USD


Hikma Pharmaceuticals Plc Fundamental data and company key figures of the share

Annual reports in USD
Key figures 15-06-2021
Cash flow
Net operating cash flow 464.000.000
Capital Expenditures -224.000.000
Free cash flow 240.000.000
Balance sheet
Total Equity 2.135.000.000
Liabilities & Shareholders equity 4.135.000.000
Income statement
Net income 431.000.000
Eps (diluted) 1,870
Diluted shares outstanding 230.499.000
Net sales/revenue 2.341.000.000

Fundamental ratios calculated on: 25-01-2022

Ratios
Key figures 25-01-2022
Cash flow
P/C 13,39
   
P/FC 25,88
Balance sheet
ROI10,42
ROE51,63
Income statement
P/E14,41
Div. Yield1,71%
P/B2,91
P/S2,65


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
SymbolHKMPF
Market Capitalization6.211.948.032,00 USD
CountryUnited Kingdom
IndicesFTSE 100
SectorsPharmaceuticals
Raw Data SourceIFRS in Millionen USD
Stock Split
Internetwww.hikma.com


Description of the company

Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company develops, manufactures and markets a range of branded and non-branded generic pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms, across the United States, the Middle East and North Africa (MENA) region and Europe. The Company's segments include Branded, Injectables, Generics and Others. The Branded business sells branded generics and in-licensed products across the MENA region and other markets. The Injectables business sells specialized generic injectable products across the globe. The Generics business sells non-injectable generic products in the United States. The Branded business has approximately 380 products in over 1,120 dosage forms and strengths. Its products include Amoclan, Blopress, Omnicef, Prograf and Suprax. The Injectables business' products include Argatroban, Fentanyl, Glycopyrrolate, Nicardipine and Phenylephrine.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov, www.hikma.com


NEWS


Earnings playbook: A complete guide to this week's reports, including the first of tech

2022-01-23
Microsoft, Tesla and Apple will release quarterly results, alongside a handful of other tech firms. McDonald's and Boeing will also offer updates.

Markets are expected to remain on edge as the Fed meets in the week ahead

2022-01-21
The Federal Reserve's meeting trumps everything else for markets in the week ahead, as investors await any new clues on its plans to raise interest rates.

Netflix quietly admits streaming competition is eating into growth

2022-01-20
Netflix added a line in its quarterly shareholder letter acknowledging streaming competition is affecting its "marginal growth."

Hikma Pharmaceuticals upgraded to Buy from Hold at Peel Hunt

2022-01-20
Peel Hunt analyst Miles D... HKMPF

Hikma Ventures leads Series A extension in NuvoAir to support its platform for patient-centric care and clinical trials

2022-01-19
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces that its venture capital arm, Hikma Ventures has led a $11 million USD round of financing for NuvoAir, a leading digital health company for chronic disease management and decentralized clinical trials that focuses on complex patients, initially targeting respiratory conditions such as COPD and asthma. The investment is an extension of the Series A round that was previously announced by NuvoAir in June 2021. Th

Microsoft's $68.7 billion deal for Activision once again shows big tech's dominance over legacy media

2022-01-18
Microsoft takes big $68.7 billion swing on video game company Activision Blizzard while legacy media stays on sidelines

Hikma expands into Canada with acquisition of Teligent sterile injectable assets

2022-01-17
Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces that it has agreed to acquire the Canadian assets of Teligent Inc. (Teligent) for $45.75 million. The transaction is expected to be completed before the end of the first quarter of 2022.

Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that

2022-01-13
President Biden urged companies to voluntarily impose Covid vaccination rules on workers after the Supreme Court blocked a government order to do that.

Two of Sen. Kyrsten Sinema's former aides have lobbied for corporate giants looking to influence Joe Biden's agenda

2022-01-11
Two of Sen. Kyrsten Sinema's former aides have become key aides for corporate giants looking to impact President Joe Biden's agenda.

Hikma Pharmaceuticals (HKMPF) presents at 40th JPMorgan Annual Healthcare Conference (Slideshow)

2022-01-11
The following slide deck was published by Hikma Pharmaceuticals PLC in conjunction with this event.